PHIO
Phio Pharmaceuticals Corp.Company Information
- Company Name
- Phio Pharmaceuticals Corp.
- CIK
- CIK0001533040
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- PHIO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- PHIO
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-09-29
- Last sale
- —
- Shares purchased (TTM)
- 80,500
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 633,958
- Shares outstanding
- 11,617,250
- Ownership
- 5.46%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 6.60%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 13 | 17 | 21 | 11 | 11 | 13 | 5 | 5 | 5 | 6 | 8 | 8 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 14 | 17 | 21 | 11 | 11 | 13 | 6 | 6 | 5 | 7 | 9 | 9 | ||||||
| Cash | - | - | - | - | - | - | - | - | - | - | 8 | 8 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | ||||||
| Restricted Cash | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 14 | 17 | 21 | 12 | 11 | 13 | 6 | 6 | 5 | 7 | 9 | 10 | ||||||
| Operating Lease Right Of Use Asset | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts Payable Current | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | ||||||
| Other Assets Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Accrued Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
| Liabilities Current | - | - | - | - | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Liabilities | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 2 | 2 | ||||||
| Operating Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 176 | 176 | 175 | 163 | 160 | 160 | 151 | 150 | 147 | 147 | 147 | 145 | ||||||
| Retained Earnings Accumulated Deficit | -163 | -159 | -155 | -153 | -150 | -148 | -146 | -145 | -143 | -141 | -139 | -137 | ||||||
| Liabilities And Stockholders Equity | 14 | 17 | 21 | 12 | 11 | 13 | 6 | 6 | 5 | 7 | 9 | 10 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 13 | 16 | 20 | 10 | 10 | 12 | 5 | 5 | 4 | 6 | 8 | 7 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | 0 | - | - | - | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | - | - | 0.00 | 0.00 | 0.00 | 0.00 | - | - | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | - | - | 10 | 100 | 100 | 100 | - | - | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | - | - | 0 | 0 | 0 | 0 | - | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | - | - | 0 | 0 | 0 | 0 | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | 0.00 | - | - | - | 0.00 | 0.00 | ||||||
| Common Stock Shares Issued | 12 | 12 | 12 | 6 | 5 | 5 | 2 | 1 | 1 | 1 | 0 | 0 | ||||||
| Shares Outstanding | 12 | 12 | 12 | 6 | 5 | 5 | 2 | 1 | 1 | 1 | 0 | 0 | ||||||
| Temporary Equity Shares Authorized | - | - | - | - | - | - | 10 | - | - | - | 10 | 0 | ||||||
| Temporary Equity Shares Issued | - | - | - | - | - | - | 0 | - | - | - | 0 | 0 | ||||||
| Temporary Equity Shares Outstanding | - | - | - | - | - | - | 0 | - | - | - | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialPhio Pharmaceuticals Corp. (PHIO) — SEC Financial Statements & Analysis
Phio Pharmaceuticals Corp. (PHIO) is a pharmaceutical preparations company, incorporated in DE. Phio Pharmaceuticals Corp. trades on Nasdaq as: PHIO. Phio Pharmaceuticals Corp. (PHIO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Phio Pharmaceuticals Corp. carries a market cap of $11.91M, a P/E ratio of -0.92x, a P/B ratio of 0.94x, an enterprise value of $-1.09M, and an EV/EBITDA multiple of 0.08x. On profitability, it posts a Return on Equity (ROE) of -113.71% and a Return on Assets (ROA) of -100.78%. Per share, it reports EPS of $-1.11, diluted EPS of $-1.48, free cash flow per share of $-1.05, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 82.13% year-over-year and EPS growth of -24.83% year-over-year. On the balance sheet, it maintains a current ratio of 9.36x, a quick ratio of 8.93x, working capital of $10.09M, a debt-to-equity ratio of 0.12x, a debt ratio of 0.11, an interest coverage ratio of -73.76x, free cash flow of $-12.21M (TTM), and net debt of $-13.00M. Figures sourced from SEC EDGAR.
- Market Cap
- $11.91M
- P/E TTM
- -0.92x
- EPS TTM
- $-1.11
- P/B TTM
- 0.94x
- ROE TTM
- -113.71%
- ROA TTM
- -100.78%
- Debt To Equity
- 0.12x
- Free Cash Flow TTM
- $-12.21M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Phio Pharmaceuticals Corp. in?
Phio Pharmaceuticals Corp. (PHIO) operates in the Pharmaceutical Preparations industry.
What exchange does PHIO trade on?
Phio Pharmaceuticals Corp. (PHIO) trades on the Nasdaq.
Where is Phio Pharmaceuticals Corp. incorporated?
Phio Pharmaceuticals Corp. is incorporated in DE.
When was Phio Pharmaceuticals Corp. (PHIO)'s most recent SEC filing?
Phio Pharmaceuticals Corp. (PHIO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is PHIO's market cap?
Phio Pharmaceuticals Corp. (PHIO) has a market capitalization of $11.91M as of 2026-06-30.
What is PHIO's EPS (earnings per share)?
Phio Pharmaceuticals Corp. (PHIO)'s trailing twelve month EPS is $-1.11 as of 2026-06-30.
What is PHIO's ROE (return on equity)?
Phio Pharmaceuticals Corp. (PHIO)'s trailing twelve month Return on Equity (ROE) is -113.71% as of 2026-06-30.
What is PHIO's ROA (return on assets)?
Phio Pharmaceuticals Corp. (PHIO)'s trailing twelve month Return on Assets (ROA) is -100.78% as of 2026-06-30.
What is PHIO's EV/EBITDA?
Phio Pharmaceuticals Corp. (PHIO)'s trailing twelve month EV/EBITDA is 0.08x as of 2026-06-30.